Skip to main content
Clinical Trials/TCTR20160122002
TCTR20160122002
Not yet recruiting
未知

A randomized controlled trial of a regular diet as the first meal compared with traditional feeding in patients undergoing cesarean section

amphun Hospital0 sites438 target enrollmentJanuary 22, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
diet after cesarean section
Sponsor
amphun Hospital
Enrollment
438
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 22, 2016
End Date
January 31, 2017
Last Updated
last year
Study Type
Interventional
Sex
Female

Investigators

Sponsor
amphun Hospital

Eligibility Criteria

Inclusion Criteria

  • Pregnant women who were scheduled to undergo
  • section for various indications were enrolled in the
  • study after informed consent might have been

Exclusion Criteria

  • The exclusion criteria included women with
  • severe uncontrolled medical conditions, e.g. diabetes mellitus, severe
  • pre\-eclampsia/eclampsia where patient needed intensive
  • care in labour and post\-partum, previous
  • bowel injury and previous surgery that involved
  • extensive lysis of adhesions of bowel.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial HypercholesterolemiaHypercholesterolaemiaMedDRA version: 20.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2017-001903-60-DKSanofi-aventis recherche & développement500
Active, not recruiting
Phase 1
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial HypercholesterolemiaHypercholesterolaemiaMedDRA version: 20.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2017-001903-60-HUSanofi-aventis recherche & développement500
Active, not recruiting
Phase 1
Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia (CAH)MedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2020-004381-19-ESeurocrine Biosciences, Inc.81
Active, not recruiting
Phase 1
This is a Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs)Moderate to Severe Rheumatoid ArthritisMedDRA version: 23.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2020-005303-39-GRAbbVie Deutschland GmbH & Co. KG425
Active, not recruiting
Not Applicable
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 16.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2013-002343-29-SKRegeneron Pharmaceuticals, Inc.803